Please ensure Javascript is enabled for purposes of website accessibility
Gilead Sciences Stock Quote

Gilead Sciences (NASDAQ: GILD)

Price as of June 9, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead Sciences Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
GILD +25.68% +9.03% +1.74% +12,289%
S&P +2.57% +53.56% +8.96% +921%

Gilead Sciences Company Info

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.

News & Analysis

The Fool has written over 1,800 articles on Gilead Sciences.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.